Stop Diabetic Complications
With Nervantage
Benfotiamine, a derivative of thiamine (vitamin B1), was an invention of Japanese scientists and there is a U.S. patent on benfotiamine that was entered by the Japanese back in 1962. Japanese benfotiamine is considered the purest source of bulk benfotiamine and is favored by manufacturers globally who insist on the highest quality in their benfotiamine product.
BenfotiamineÕs safety has been proven over 12 years of use in Europe for the treatment and prevention of diabetic complications among others. The patent on benfotiamine gave information that it is even less toxic than common vitamin B1 (thiamine hydrochloride usually). This patent was submitted in the United States in 1962 by the Japanese.
Vitamin B1 has a long history of use as an oral supplement without reported adverse effects. Due to its therapeutic action in some frequently observed clinical syndromes, thiamine hydrochloride has been advised and used over a long period of time. There are no reports of adverse effects of oral thiamine, even at dosages of several hundred milligrams a day (SCOGS, 1978; DHEW, 1979; Marks, 1989).
Benfotiamine has shown to be very safe. To date, there have been no reports of any known, negative interactions with any medications. To the contrary, some medications actually can cause a thiamine deficiency in some people and benfotiamine could correct this serious situation.
Many researchers, medical experts, doctors, podiatrists and many medical publishers recommend benfotiamine for neuropathy, retinopathy nephropathy, heart/circulatory complications and B1 deficiencies. Any in depth study on the web will produce physicians, naturopaths, neurologists, optometrists, chiropractors, etc. who have very positive feelings about the effectiveness and potential of benfotiamine in terms of the research done to date on this important tool in the arsenal against neuropathy, retinopathy and beneficial for the heart and circulatory system. We have professional healthcare providers from all of these disciplines which shows the confidence the medical community has in the purity and bioavailability of our benfotiamine product.
Dr. David Williams, publisher of ÒAlternatives NewsletterÓ, wrote an in depth article concerning benfotiamine in his May, 2004 issue. This article is an eye opener in terms of how effective benfotiamine can be for many health conditions. If possible, it would be beneficial for any interested reader to take a look at this article. http://www.drdavidwilliams.com/
Dr Paul Chous is another medical professional who sees the merits of benfotiamine:
"I suspect strongly that benfotiamine will mitigate (or, hopefully, prevent) DRT in humans, but the burden of proof has not yet been met. The case for symptomatic relief of neuropathy symptoms is, of course, more tangible."
In conclusion, the consensus for benfotiamine is very positive. The benefits are worth investigating. If you or anyone you know is a diabetic, the protection against diabetic complications makes benfotiamine a viable tool in their arsenal to protect themselves. If they already are experiencing complications such as neuropathy, retinopathy, and others they will benefit from possible decrease in the progression along with pain relief in terms of peripheral neuropathy and other neuropathies.
Supports Diabetic Complications
- Blocks damage by Hyperglycemia
- Support for Diabetic Retinopathy
- Support for Diabetic Neuropathy
- Support for Diabetic Nephropathy
Great for These Non-Diabetic Conditions- Sciatica
- Heart/Vascular health
- Fibromyalgia
- Nerve Health-AntiAging
- Safe For Long Term Use
- Satisfaction Guaranteed
Benfotiamine, a synthetic variant of vitamin B1, can help prevent nerve and blood-vessel damage caused by diabetes. Three of the main complications of diabetes are nerve damage, circulatory difficulties and vision problems. These symptoms are caused by a build-up of sugar in the cells. Changes in insulin and glucose tolerance with age sometimes referred to as age-related diabetes similar symptoms have often been considered part of the aging process.
Now researchers have reported that Benfotiamine halts much of that sugar accumulation by boosting three pathways inside the cell. This could result in a vastly improved quality of life for those with the disease and those suffering the age-related symptoms.
References:
1. Hammes HP, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med. 2003 Mar;9(3):294-9.
2. Stracke H, et al. Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral nerves in diabetic rats. Exp Clin Endocrinol Diabetes. 2001;109(6):330-6.
benfotiamine Diabetes renal disease Polyneuropathy Neuropathy
NEW YORK (Reuters Health) Sept 22 - Benfotiamine prevents the endothelial dysfunction and oxidative stress that follow a meal rich in advanced glycation end (AGE) products in type 2 diabetics, according to a report in the September issue of Diabetes Care.
"Benfotiamine was used for decades as a treatment of diabetic neuropathy, without any exact knowledge of the beneficial mechanism," Dr. Alin Stirban from Ruhr-University, Bochum, Germany told Reuters Health. "Our data bring benfotiamine from the relatively restricted field of diabetic neuropathy into the much larger field of vascular function and prove in humans effects previously postulated."
Dr. Stirban and colleagues investigated the effects of a real-life, cooked, AGE-rich meal on endothelial function and oxidative stress with or without benfotiamine pretreatment in 13 adults with type 2 diabetes.
The high-AGE meal significantly impaired endothelium-dependent vasodilatation, the authors report, but this impairment was completely prevented by benfotiamine.
The high-AGE meal, with or without benfotiamine pretreatment, did not affect endothelium-independent vasodilatation, the results indicate.
Benfotiamine pretreatment also prevented the decrease in reactive hyperemia and the increase in circulating markers of endothelial dysfunction, inflammation, and oxidative stress seen after a high-AGE meal, the researchers note. The beneficial effects of benfotiamine treatment were accompanied by lower serum levels of AGEs and dicarbonyls, the report indicates.
"Our study does not completely elucidate the mechanisms through which benfotiamine prevents postprandial vascular dysfunction but raises some hypotheses," the authors conclude. "Further studies are warranted to bring light into these subtle mechanisms."
"We intend to investigate in a placebo-controlled manner medium-term effects of benfotiamine on endothelial function," Dr. Stirban said. "But we will extend our observation also on other cell types of critical importance for people with diabetes, such as adipocytes."
Diabetes Care 2006;29:2064-2071
|
|
